Inhaled Steroids, Sex and Emphysema Index – Clinical Parameters with Impact on the Effectiveness of Valve Implantation in Patients with Severe Emphysema
Markus Polke,Jonas Brugger,Matthias Rötting,Nilab Polke,Judith Brock,Stefanie Schuler,Ines Richter,Ralf Eberhardt,Daniela Gompelmann,Felix JF Herth
DOI: https://doi.org/10.2147/COPD.S361256
2022-06-21
International Journal of COPD
Abstract:Markus Polke, 1 Jonas Brugger, 2 Matthias Rötting, 3 Nilab Polke, 1 Judith Brock, 1 Stefanie Schuler, 1 Ines Richter, 1 Ralf Eberhardt, 1, 4, 5 Felix JF Herth, 1, 5 Daniela Gompelmann 1, 5, 6 1 Pneumology and Critical Care Medicine, Thoraxklinik at University of Heidelberg, Heidelberg, Germany; 2 Institute for Medical Statistics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University Vienna, Vienna, Austria; 3 Medizinische Klinik V, Klinikum Fulda, Fulda, Deutschland; 4 Pneumologie & Internistische Intensivmedizin, Asklepios Klinik Barmbek, Hamburg, Deutschland; 5 Translational Lung Research Center Heidelberg (TLRCH, German Center for Lung Research (DZL), Heidelberg, Germany; 6 Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, Vienna, Austria Correspondence: Markus Polke, Pneumology and Critical Care Medicine, Thoraxklinik at University of Heidelberg, Heidelberg, Germany, Email Aims and Objectives: Many patients with chronic obstructive lung disease suffer from emphysema. Valve implantation may be a reasonable method in patients presenting advanced emphysema and absent interlobar collateral ventilation (CV). However, other clinical parameters influencing the effectiveness of endoscopic lung volume reduction (ELVR) are not well known. Methods: COPD patients with advanced emphysema who received valve implantation in 2016 were retrospectively analyzed. The following characteristics were collected prior to valve implantation: age, sex, body mass index, presence of allergies, use of inhaled corticosteroids (ICS), lung function parameters, diffusion capacity, 6-minute walk distance (6-MWD), blood gases, COHb, smoking history, and emphysema index (quantitative multi-detector computed tomography). Three months following valve implantation, lung function parameters, diffusion capacity, 6-MWD and blood gases were measured. In this analysis, we evaluated the impact of these variables on an increase in FEV 1 and 6-MWT as well as a decrease in RV three months after valve implantation. Results: Overall, 77 COPD patients (57% male, mean age 66, mean FEV 1 32%, mean RV 259%) who underwent valve therapy were enrolled. At 3-month follow-up, patients experienced a mean FEV 1 increase of 0.09 ± 0.21 L, a mean RV decrease of 0.42 ± 1.80 L and a mean improvement of 8.3 ± 57 m in the 6-MWT. Overall, ICS, sex and emphysema index had an impact on the outcome following ELVR: ICS medication was associated with inferior FEV 1 outcome. The higher the emphysema index, the less the RV reduction. Sex was a predictor for change of FEV 1 (%), RV (L), and 6-MWT: male patients seem to benefit less than female patients from valve implantation. Conclusion: These findings suggest that ICS, emphysema index and sex are clinical parameters that may be associated with inferior outcome following ELVR. Further studies have to confirm these results to improve patient selection and clinical outcome of ELVR. Keywords: COPD, emphysema, valve implantation, lung volume reduction Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and expected to become the leading cause of death in the world in around fifteen years. 1 Many patients with COPD suffer from emphysema and disease severity depends on its extent. 2 The main causes of emphysema are environmental or occupational exposure to substances and alpha-1 anti-trypsin (AAT) deficiency. 3 Endoscopic lung volume reduction (ELVR) and lung volume reduction surgery (LVRS) may be beneficial in some of these individuals. In patients with upper lobe-predominant emphysema, lung volume reduction surgery can minimize hyperinflation and thus lead to improvements in lung function, exercise capacity, and quality of life and is associated with survival benefits. 4 However, LVRS is associated with a risk of morbidity and mortality. Therefore, an alternative and less invasive method of lung volume reduction was invented: endoscopic lung volume reduction (ELVR). Besides some other interventional methods, endoscopic valve implantation is the best studied technique, resulting in lobar atelectasis of the emphysematous lung lobe and thus in a reduction of symptoms and improvement of long-term outcomes. 5–8 Although the valve implantation is a minimally invasive therapy, it can be associated with complications. The most frequent complication in valve implantation is pneumothorax in around a quarter of patients. 5,6,8 The preva -Abstract Truncated-